Johnson & Johnson published data on Friday showing that 75% of patients were free from atrial arrhythmia recurrence one year after being treated with its Varipulse pulsed field ablation (PFA) device ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Johnson & Johnson failed to capitalize on the pulsed field ...

Johnson & Johnson, Boston Scientific and Abbott were among the companies showcasing new data on atrial fibrillation treatments, including pulsed field ablation catheters.

Johnson & Johnson (NYSE:JNJ) has decided to resume a limited market rollout of its heart rhythm device Varipulse after an investigation indicated no safety concerns, the MedTech giant announced.

After more than a monthlong pause in response to four neurovascular events linked to its Varipulse pulsed-field ablation system, Johnson & Johnson announced late last week that it will resume use of ...

Johnson & Johnson (NYSE: JNJ) traded lower on Wednesday after the MedTech giant disclosed a temporary pause in U.S. cases treated with its Varipulse Pulsed Field Ablation Platform, which targets the ...

Bengaluru: Johnson & Johnson said on Friday it resumed the limited market release of its Varipulse heart device in the United States after an investigation found the devices operate as intended. In ...

First regulatory approval for the first-of-its-kind, fully-integrated PFA system with a simple and reproducible workflow Integrated with the world's leading CARTO™ 3D cardiac mapping system for the ...

On Wednesday, Johnson & Johnson (NYSE:JNJ) said it has temporarily paused all U.S. cases using its Varipulse pulsed field ablation (PFA) system. Pulsed-field ablation (PFA) is a non-thermal procedure ...

Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Johnson & Johnson said the U.S. rollout of the Varipulse pulsed ...

NEW BRUNSWICK - Johnson & Johnson said on Jan 8 it had temporarily paused the rollout of its Varipulse heart device in the United States, as the company investigates four reported stroke events. The ...

The US Food and Drug Administration has approved the Varipulse pulsed-field ablation (PFA) system for the treatment of drug-refractory paroxysmal atrial fibrillation (AF), device manufacturer Johnson ...